Sterile Injectable Drugs Market Business Strategies and Financial Status over Forecast Period 2017-2025

Injectable drug delivery is the introduction of a drug or drugs to a patient with the help of a delivery device such as a needle and syringe. It is essential that the injectable drug delivery is sterile. Sterile injectable drugs are usually formulated in liquid form and they allow the transport of drugs directly into the body through circulating blood, even though they may be designed to transport the drug to a specific part of the body.

Rise in chronic diseases across the world, especially cancer and diabetes; increase in focus of drug manufacturers on research and development of anti-cancer drugs; swift approvals by the FDA in the case of sterile injectables; coupled with short approval timelines for new drug for the treatment of cancer are the key factors boosting demand for sterile injectables in the global market. Manufacture and expansion of sterile injectable drug products are complex and cost-oriented. Manufacturing and handling costs of sterile injectable drugs are comparatively higher than conventional dosage forms as the former needs to be sterilized before or during manufacturing. Furthermore, in the U.S., the FDA has imposed stringent regulations on the facilities and equipment involved in the manufacture of sterile injectable drugs, as these are highly toxic and infectious. Therefore, a high level of quality and care is essential in the manufacture, packaging, storage, and distribution of sterile injectable drugs.

The global sterile injectable drugs market can be segmented based on type of drug, type of device used, application, route of administration, molecule type, and distribution channel. In terms of type of drug, the market can be sub-segmented into monoclonal antibodies, cytokines, peptide hormones, vaccines, peptide antibiotics, insulin, blood factors, immunoglobulin, and others. In terms of type of device used, the market can be further divided into disposable syringes, reusable needles, pre-filled syringes, needle-free injectors, auto-injectors, and pen-needles. Based on application, the sterile injectable drugs market can be segmented into cancer, diabetes, musculoskeletal, CNS, cardiovascular diseases, and infection. The cancer application segment is dominant in the market, as several drugs for the treatment of cancer are currently developed in biologic form. In terms of route of administration, the sterile injectable drugs market can be segmented into intravenous (IV), intramuscular (IM), subcutaneous (SC), intraperitoneal, and others. Based on molecule type, the sterile injectable drugs market can be categorized into small molecules and large molecules. The large molecules segment dominates the market, as there are numerous biologics manufactured as sterile injectable drugs for the treatment of cancer. In terms of distribution channel, the market can be segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Geographically, the sterile injectable drugs market can be segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America leads the market, followed by Europe. However, the sterile injectable drug market is anticipated to grow rapidly in the emerging countries in Asia Pacific and Latin America, owing to high incidence of chronic diseases such as cancer and diabetes in the countries, coupled with rise in compliance of patients with regard to novel technologies of treatment. Additionally, drug manufacturers are focused on the emerging countries due to swift approvals and lower competition in entering the market in these regions.

Request for an in-depth table of contents for this report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=34427

Key players in the global sterile injectable drugs market include Baxter International, Inc., Becton, Sanofi, Pfizer, Inc., GlaxoSmithKline plc, Dickinson and Company, Antares Pharma, Inc., Merck & Co., Inc., Johnson & Johnson Services, Inc., Novartis AG, and Nova Nordisk A/S.